CDK

Cat. No.

A54468

CAS No.

2927473-94-5

CDK2-IN-27

CDK2-IN-27 is a selective inhibitor of cyclin-dependent kinase 2 (CDK2), demonstrating potent inhibition with IC50 values of less than 10 nM for the CDK2/cyclin E1 complex and 10-20 nM for the CDK2/cyclin B1 complex. This compound is crucial for studies focused on cell cycle regulation and cancer research, where CDK2 plays a significant role in cell proliferation. CDK2-IN-27 provides valuable insights into therapeutic strategies targeting CDK2 to halt tumor growth and enhance cancer treatment regimens.

Cat. No.

A54470

CAS No.

1056016-06-8

(R)-DRF053

(R)-DRF053 is a selective cyclin-dependent kinase (CDK) inhibitor that primarily targets Cdk5. This compound is known to enhance the formation of ductal precursor β cells, making it valuable for investigating pancreatic development and diabetes research. Additionally, (R)-DRF053 has been shown to inhibit Dil-ox-LDL uptake and reduce CD36 gene expression induced by advanced glycation end products (AGEs) in U937 cells, indicating its relevance in studies related to atherosclerosis and metabolic diseases.

Cat. No.

A54472

CAS No.

660822-23-1

CCT68127

Synonyms: αSβR-21

CCT68127 is a selective inhibitor of cyclin-dependent kinases (CDKs) that functions by disrupting cell cycle progression. This compound demonstrates significant anti-proliferative activity in various cancer cell lines, making it a valuable tool for cancer research. CCT68127 can be utilized to investigate CDK-related pathways and explore potential therapeutic strategies for malignancies.

Cat. No.

A54473

CAS No.

500735-47-7

Olomoucine II

Olomoucine II is a potent inhibitor of cyclin-dependent kinases (CDKs), specifically exhibiting IC50 values of 0.06 µM for CDK9/cyclin T, 0.1 µM for CDK2/cyclin E, 0.45 µM for CDK7/cyclin H, 7.6 µM for CDK1/cyclin B, and 19.8 µM for CDK4/cyclin D1. This compound demonstrates significant antiproliferative activity, making it a valuable tool for studies investigating cell cycle regulation and cancer biology. Its selectivity and efficacy position Olomoucine II as an important reagent for research applications aimed at understanding CDK-related pathways.

Cat. No.

A54474

CAS No.

1203565-13-2

CDK modulator 1

CDK Modulator 1 functions as a selective inhibitor of cyclin-dependent kinases (CDKs), influencing cell cycle progression. This compound has shown significant biological activity in blocking CDK activity, making it a valuable tool for research in cancer biology and cell proliferation studies. It is particularly useful in investigations related to cancer therapeutics and the regulation of cellular growth control pathways.

Cat. No.

A54476

CAS No.

677701-62-1

CDK1/2/4-IN-2

CDK1/2/4-IN-2 is a selective inhibitor of cyclin-dependent kinases 1, 2, and 4. This compound demonstrates significant anti-proliferative effects, making it a valuable tool for investigating cell cycle regulation and cancer biology. It is suitable for use in preclinical studies aimed at exploring therapeutic strategies for various malignancies.

Cat. No.

A54478

CAS No.

730945-59-2

CDK2-IN-39

CDK2-IN-39 is a selective inhibitor of cyclin-dependent kinase 2 (CDK2), a crucial regulator of the cell cycle. This compound demonstrates significant activity in modulating CDK2-mediated phosphorylation, making it a valuable tool for studies on cell proliferation, cancer research, and cellular signaling pathways. CDK2-IN-39 can help elucidate the role of CDK2 in the progression of various cancers and may aid in the development of therapeutic strategies targeting cell cycle dysregulation.

Cat. No.

A54479

CAS No.

2991229-06-0

CDK2-IN-21

CDK2-IN-21 is a selective inhibitor of cyclin-dependent kinase 2 (CDK2) with an IC50 of 0.24 µM. This compound demonstrates potent inhibitory activity, making it a valuable tool for cancer research. By targeting CDK2, CDK2-IN-21 can help elucidate the role of cell cycle regulation in tumorigenesis and facilitate the development of potential therapeutic strategies against cancer.

Cat. No.

A54480

CAS No.

477588-78-6

ZK 304709

ZK 304709 is a multi-target cyclin-dependent kinase (CDK) inhibitor that plays a critical role in cell cycle regulation. It effectively inhibits various CDKs, thereby preventing proliferation in cancer cells. This compound is valuable for studying mechanisms of cell cycle control and can aid in the development of novel therapeutic strategies against cancer.

Cat. No.

A77694

CAS No.

3030492-40-8

HZ1

HZ1 is a selective inhibitor of cyclin-dependent kinase-like 3 (CDKL3) that operates via targeted inhibition of this kinase. It demonstrates significant tumor-suppressive activity and has potential to circumvent resistance to CDK4/6 inhibitors. This compound is applicable in cancer research, particularly in studies focused on cell cycle regulation and therapeutic resistance mechanisms.

Cat. No.

A81287

CAS No.

2603381-71-9

CDK7 ligand 2

CDK7 ligand 2 is a selective inhibitor targeting CDK7, a crucial cyclin-dependent kinase involved in transcription regulation. This compound exhibits significant potential in drug discovery and development, particularly in the synthesis of PROTACs (Proteolysis Targeting Chimeras). Its application in research may facilitate novel therapeutic approaches for diseases associated with abnormal transcriptional control.

Cat. No.

B10863

CAS No.

2310135-61-4

(S)-Purvalanol B

Synonyms: (S)-NG 95

(S)-Purvalanol B is the S enantiomer of Purvalanol B, a selective inhibitor of cyclin-dependent kinases (CDKs). This compound effectively disrupts the activity of CDKs, which play a critical role in cell cycle regulation and cellular proliferation. Due to its unique targeting mechanism, (S)-Purvalanol B is valuable in cancer research, particularly in studies related to cell cycle dysregulation and therapeutic strategies for tumor proliferation control.

Cat. No.

B20113

CAS No.

101622-50-8

Iso-Olomoucine

Iso-Olomoucine is an inactive stereoisomer of the CDK5 inhibitor olomoucine, exhibiting an IC50 value greater than 1 mM. It serves as a valuable control in experiments assessing CDK5 activity and modulation. This compound is primarily used in research applications focused on neurological disorders and cell cycle regulation, providing insights into the mechanisms of CDK5 inhibition.

Cat. No.

B21894

CAS No.

1879980-97-8

CDK8-IN-2

CDK8-IN-2 is a potent inhibitor of cyclin-dependent kinase 8 (CDK8) with an IC50 value of 0.010 μM, and it also demonstrates activity against CDK19 with an IC50 of 0.026 μM. This compound effectively inhibits phospho-STAT1, serving as a pharmacodynamic biomarker for CDK8 activity, while also reducing WNT pathway activity. CDK8-IN-2 is suitable for research focused on colorectal carcinoma and offers insights into CDK8's role in tumorigenesis and cellular signaling pathways.

Cat. No.

B21897

CAS No.

2640208-32-6

CDK7-IN-33

CDK7-IN-33 is an inhibitor of CDK7 kinase, characterized by its pyrimidine structure. This compound demonstrates potent inhibitory activity, making it valuable in research applications related to cancer, inflammation, cardiovascular diseases, infectious diseases, immune disorders, and metabolic conditions. Its selective modulation of CDK7 activity highlights its potential for therapeutic exploration in various pathological contexts.

Cat. No.

B21927

CAS No.

2377487-13-1

CTX-439

CTX-439 is a potent, orally active ATP-competitive inhibitor targeting CDK12 and CDK13, with an IC50 of 3.1 nM for CDK12 and 9.2 nM for CDK13. This small-molecule compound is effective in inducing DNA damage and apoptosis in tumor cells. CTX-439 is particularly relevant for research focused on breast and ovarian cancer therapies.

Cat. No.

B21937

CAS No.

3079792-42-7

CDK9 ligand 5

CDK9 Ligand 5 is a selective inhibitor of cyclin-dependent kinase 9 (CDK9), a critical regulator of transcriptional control. This compound serves as a valuable ligand for the design and development of PROTACs (Proteolysis Targeting Chimeras) aimed at degrading CDK9, exemplified by the PROTAC CDK9 degrader-9. CDK9 Ligand 5 is particularly relevant in cancer research, where CDK9 activity plays a pivotal role in cell proliferation and survival.

Cat. No.

B21964

CAS No.

802536-13-6

CDK2-IN-56

CDK2-IN-56 is a selective inhibitor of cyclin-dependent kinase 2 (CDK2). This compound, classified as a pyrazoloquinazoline-3-carboxamide, demonstrates significant inhibitory activity against CDK2 while also affecting cyclin A. CDK2-IN-56 is primarily utilized in cancer research, providing valuable insights into cell cycle regulation and potential therapeutic strategies targeting CDK2-related pathways.